An easy access to healthcare facilities is boosting growth in the market.
Australia’s diabetes assays market, which declined in 2020 amidst the COVID-19 pandemic, is expected to recover in 2021 as the necessity to screen and monitor diabetes patients is driving the market, according to a report from GlobalData.
Glycated hemoglobin (HbA1c) POC assays and HbA1c laboratory assays accounted for more than 90% of the market in 2020.
“High quality diabetic care management and easy access to healthcare facilities in Australia are expected to boost the diabetes assays market growth,” GlobalData’s medical devices analyst Gundreddy Gopinadh commented.
Furthermore, there is a growing awareness about the importance of diagnosis, regular screening of high risk population, and proper use of government schemes like the National Diabetes Services Scheme and Medicare Safety Nets Scheme to limit the out of pocket spending, Gopinadh added.
Do you know more about this story? Contact us anonymously through this link.